Exact Mass: 385.3192

Exact Mass Matches: 385.3192

Found 121 metabolites which its exact mass value is equals to given mass value 385.3192, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

NCIOpen2_008278

3beta-(1-Pyrrolidinyl)-5alpha-pregnane-11,20-dione

C25H39NO2 (385.2981)


   

3-Hydroxy-cis-5-tetradecenoylcarnitine

(3R)-3-{[(5Z)-3-hydroxytetradec-5-enoyl]oxy}-4-(trimethylazaniumyl)butanoic acid

C21H39NO5 (385.2828)


3-Hydroxy-cis-5-tetradecenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-3-hydroxytetradec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-cis-5-tetradecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-cis-5-tetradecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-cis-5-tetradecenoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). 3-Hydroxy-cis-5-tetradecenoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane.  Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Fistulosin

1,2-dihydro-2-Octadecyl-3H-indol-3-one

C26H43NO (385.3344)


Fistulosin is found in onion-family vegetables. Fistulosin is an alkaloid from the roots of Allium fistulosum (Welsh onion). Alkaloid from the roots of Allium fistulosum (Welsh onion). Fistulosin is found in onion-family vegetables.

   

Pentadecanoylcarnitine

3-(pentadecanoyloxy)-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


Pentadecanoylcarnitine is an acylcarnitine. More specifically, it is an pentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine pentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane.  Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

13-Methyltetradecanoylcarnitine

3-[(13-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


13-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-Methyltetradecanoylcarnitine

3-[(11-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


11-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Methyltetradecanoylcarnitine

3-[(10-Methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C22H43NO4 (385.3192)


10-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methyltetradecanoylcarnitine

3-[(8-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


8-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Methyltetradecanoylcarnitine

3-[(9-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


9-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methyltetradecanoylcarnitine

3-[(7-Methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C22H43NO4 (385.3192)


7-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methyltetradecanoylcarnitine

3-[(3-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


3-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methyltetradecanoylcarnitine

3-[(4-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


4-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methyltetradecanoylcarnitine

3-[(5-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


5-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methyltetradecanoylcarnitine

6-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


6-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Methyltetradecanoylcarnitine

3-[(12-methyltetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO4 (385.3192)


12-Methyltetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-methyltetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-Methyltetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-Methyltetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z)-9-Hydroxytetradec-6-enoylcarnitine

3-[(9-hydroxytetradec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H39NO5 (385.2828)


(6Z)-9-Hydroxytetradec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-9-hydroxytetradec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-9-Hydroxytetradec-6-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z)-9-Hydroxytetradec-6-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (6Z)-9-Hydroxytetradec-6-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (6Z)-9-Hydroxytetradec-6-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(12E)-10-Hydroxytetradec-12-enoylcarnitine

3-[(10-Hydroxytetradec-12-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H39NO5 (385.2828)


(12E)-10-Hydroxytetradec-12-enoylcarnitine is an acylcarnitine. More specifically, it is an (12E)-10-hydroxytetradec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E)-10-Hydroxytetradec-12-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E)-10-Hydroxytetradec-12-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12E)-10-Hydroxytetradec-12-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (12E)-10-Hydroxytetradec-12-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3Z)-5-Hydroxytetradec-3-enoylcarnitine

3-[(5-Hydroxytetradec-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H39NO5 (385.2828)


(3Z)-5-Hydroxytetradec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an (3Z)-5-hydroxytetradec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3Z)-5-Hydroxytetradec-3-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3Z)-5-Hydroxytetradec-3-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (3Z)-5-Hydroxytetradec-3-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (3Z)-5-Hydroxytetradec-3-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-8-Hydroxytetradec-5-enoylcarnitine

3-[(8-hydroxytetradec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H39NO5 (385.2828)


(5E)-8-Hydroxytetradec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-8-hydroxytetradec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-8-Hydroxytetradec-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E)-8-Hydroxytetradec-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (5E)-8-Hydroxytetradec-5-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (5E)-8-Hydroxytetradec-5-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-4-Hydroxytetradec-2-enoylcarnitine

3-[(4-Hydroxytetradec-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H39NO5 (385.2828)


(2E)-4-Hydroxytetradec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2E)-4-hydroxytetradec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-4-Hydroxytetradec-2-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E)-4-Hydroxytetradec-2-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (2E)-4-Hydroxytetradec-2-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (2E)-4-Hydroxytetradec-2-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-oxotetradecanoylcarnitine

3-[(3-oxotetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H39NO5 (385.2828)


3-oxotetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxotetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxotetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-oxotetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Glutamic acid

2-hexadecanamidopentanedioic acid

C21H39NO5 (385.2828)


N-palmitoyl glutamic acid, also known as N-palmitoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Stearoyl Threonine

3-hydroxy-2-octadecanamidobutanoic acid

C22H43NO4 (385.3192)


N-stearoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

4,4-Dimethyl-2-[3-carboxylatopropyl]-2-tridecyloxazolidine 3-oxide

2-(3-carboxypropyl)-4,4-dimethyl-2-tridecyl-1,3-oxazolidin-3-ium-3-olate

C22H43NO4 (385.3192)


   

hydroxytetradecenoylcarnitine

3,17-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]heptadec-5-enoate

C21H39NO5 (385.2828)


   

2-amino-3-hydroxy-2-(1-hydroxy-12-oxo-4-octadecenyl)propionic acid

2-amino-3-hydroxy-2-(1-hydroxy-12-oxo-4-octadecenyl)propionic acid

C21H39NO5 (385.2828)


   
   

Cycloxobuxoviricine

Cycloxobuxoviricine

C25H39NO2 (385.2981)


   

DTXSID00827496

DTXSID00827496

C25H39NO2 (385.2981)


   

2-octadecyl-3-indolinone|fistulosin|octadecyl 3-hydroxyindole

2-octadecyl-3-indolinone|fistulosin|octadecyl 3-hydroxyindole

C26H43NO (385.3344)


   

N,3-Di-Ac-2-Amino-1,3-octadecanediol

N,3-Di-Ac-2-Amino-1,3-octadecanediol

C22H43NO4 (385.3192)


   

1,2-diacetylsphingosine

1,2-diacetylsphingosine

C22H43NO4 (385.3192)


   

mycalazal-5

mycalazal-5

C26H43NO (385.3344)


   
   
   
   

25-azavitamin D3 / 25-azacholecalciferol

(5Z,7E)-(3S)-25-aza-9,10-seco-5,7,10(19)-cholestatrien-3-ol

C26H43NO (385.3344)


   

N-palmitoyl glutamic acid

N-hexadecanoyl-glutamic acid

C21H39NO5 (385.2828)


   

Fistulosin

1,2-dihydro-2-Octadecyl-3H-indol-3-one

C26H43NO (385.3344)


   

CAR 14:1;O

3S-{[(5Z)-3-hydroxytetradec-5-enoyl]oxy}-4-(trimethylazaniumyl)butanoate

C21H39NO5 (385.2828)


   

NA 21:2;O4

N-hexadecanoyl-glutamic acid

C21H39NO5 (385.2828)


   

NA 25:6;O

N-9-oxo-12Z-octadecenoyl-benzylamine

C25H39NO2 (385.2981)


   

NA 26:5

N-[(1S)-1-Phenylethyl]octadec-9Z-enamide

C26H43NO (385.3344)


   

(9Z,12Z)-octadeca-9,12-dienoic acid, compound with 2,2-iminodiethanol (1:1)

(9Z,12Z)-octadeca-9,12-dienoic acid, compound with 2,2-iminodiethanol (1:1)

C22H43NO4 (385.3192)


   

N,N-bis[2-(octylamino)ethyl]glycine

N,N-bis[2-(octylamino)ethyl]glycine

C22H47N3O2 (385.3668)


   

Vinyl tris(methylisobutylketoximino) silane

Vinyl tris(methylisobutylketoximino) silane

C19H39N3O3Si (385.2761)


   

2-methyloxirane,octadecanoate,oxirane

2-methyloxirane,octadecanoate,oxirane

C23H45O4- (385.3318)


   

Palmitoylglutamic acid

Palmitoylglutamic acid

C21H39NO5 (385.2828)


   

Palmitoyl glutamic acid

Palmitoyl glutamic acid

C21H39NO5 (385.2828)


   

25-Azavitamin D3

25-Azavitamin D3

C26H43NO (385.3344)


   

3beta-(1-Pyrrolidinyl)-5alpha-pregnane-11,20-dione

3beta-(1-Pyrrolidinyl)-5alpha-pregnane-11,20-dione

C25H39NO2 (385.2981)


   

3-Hydroxytetradecenoylcarnitine

3-Hydroxytetradecenoylcarnitine

C21H39NO5 (385.2828)


   

3-oxotetradecanoylcarnitine

3-oxotetradecanoylcarnitine

C21H39NO5 (385.2828)


   

8-Methyltetradecanoylcarnitine

8-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

9-Methyltetradecanoylcarnitine

9-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

7-Methyltetradecanoylcarnitine

7-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

3-Methyltetradecanoylcarnitine

3-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

4-Methyltetradecanoylcarnitine

4-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

5-Methyltetradecanoylcarnitine

5-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

6-Methyltetradecanoylcarnitine

6-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

11-Methyltetradecanoylcarnitine

11-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

10-Methyltetradecanoylcarnitine

10-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

12-Methyltetradecanoylcarnitine

12-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

(E)-3,17-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]heptadec-5-enoate

(E)-3,17-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]heptadec-5-enoate

C21H39NO5 (385.2828)


   

(6Z)-9-Hydroxytetradec-6-enoylcarnitine

(6Z)-9-Hydroxytetradec-6-enoylcarnitine

C21H39NO5 (385.2828)


   

(3Z)-5-Hydroxytetradec-3-enoylcarnitine

(3Z)-5-Hydroxytetradec-3-enoylcarnitine

C21H39NO5 (385.2828)


   

(5E)-8-Hydroxytetradec-5-enoylcarnitine

(5E)-8-Hydroxytetradec-5-enoylcarnitine

C21H39NO5 (385.2828)


   

(2E)-4-Hydroxytetradec-2-enoylcarnitine

(2E)-4-Hydroxytetradec-2-enoylcarnitine

C21H39NO5 (385.2828)


   

(12E)-10-Hydroxytetradec-12-enoylcarnitine

(12E)-10-Hydroxytetradec-12-enoylcarnitine

C21H39NO5 (385.2828)


   

3-Hydroxy-cis-5-tetradecenoylcarnitine

3-Hydroxy-cis-5-tetradecenoylcarnitine

C21H39NO5 (385.2828)


   

asperterpenoid A(1-)

asperterpenoid A(1-)

C25H37O3- (385.2743)


   

Pentadecanoyl-carnitine

Pentadecanoyl-carnitine

C22H43NO4 (385.3192)


   

Acetic acid (2S,3R)-2-(acetylamino)-3-hydroxyoctadecyl ester

Acetic acid (2S,3R)-2-(acetylamino)-3-hydroxyoctadecyl ester

C22H43NO4 (385.3192)


   

(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-2-(ethylaminomethyl)-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-2-(ethylaminomethyl)-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C23H35N3O2 (385.2729)


   

O-[(9Z)-3-hydroxytetradec-9-enoyl]carnitine

O-[(9Z)-3-hydroxytetradec-9-enoyl]carnitine

C21H39NO5 (385.2828)


An O-hydroxytetradecenoylcarnitine having (9Z)-3-hydroxytetradec-9-enoyl as the acyl substituent.

   

(8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoate

(8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoate

C26H41O2- (385.3106)


A polyunsaturated fatty acid anion that is the conjugate base of (8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoate

(11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoate

C26H41O2- (385.3106)


A hexacosapentaenoate that is the conjugate base of (11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

1-(3,7,11,15-Tetramethyl-2,6,10,14-hexadecatetrenyl)hexahydro-2H-azepin-2-one

1-(3,7,11,15-Tetramethyl-2,6,10,14-hexadecatetrenyl)hexahydro-2H-azepin-2-one

C26H43NO (385.3344)


   

N-(1,3-dihydroxyoctadecan-2-yl)pentanamide

N-(1,3-dihydroxyoctadecan-2-yl)pentanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxytetradecan-2-yl)nonanamide

N-(1,3-dihydroxytetradecan-2-yl)nonanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxypentadecan-2-yl)octanamide

N-(1,3-dihydroxypentadecan-2-yl)octanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyhenicosan-2-yl)acetamide

N-(1,3-dihydroxyhenicosan-2-yl)acetamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxynonadecan-2-yl)butanamide

N-(1,3-dihydroxynonadecan-2-yl)butanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxynonan-2-yl)tetradecanamide

N-(1,3-dihydroxynonan-2-yl)tetradecanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyhexadecan-2-yl)heptanamide

N-(1,3-dihydroxyhexadecan-2-yl)heptanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyicosan-2-yl)propanamide

N-(1,3-dihydroxyicosan-2-yl)propanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyheptadecan-2-yl)hexanamide

N-(1,3-dihydroxyheptadecan-2-yl)hexanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyoctan-2-yl)pentadecanamide

N-(1,3-dihydroxyoctan-2-yl)pentadecanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxyundecan-2-yl)dodecanamide

N-(1,3-dihydroxyundecan-2-yl)dodecanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxytridecan-2-yl)decanamide

N-(1,3-dihydroxytridecan-2-yl)decanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxydodecan-2-yl)undecanamide

N-(1,3-dihydroxydodecan-2-yl)undecanamide

C23H47NO3 (385.3556)


   

N-(1,3-dihydroxydecan-2-yl)tridecanamide

N-(1,3-dihydroxydecan-2-yl)tridecanamide

C23H47NO3 (385.3556)


   

2-Octadecyl-1H-indol-3-ol

2-Octadecyl-1H-indol-3-ol

C26H43NO (385.3344)


   

Pentadecanoylcarnitine

Pentadecanoylcarnitine

C22H43NO4 (385.3192)


   

13-Methyltetradecanoylcarnitine

13-Methyltetradecanoylcarnitine

C22H43NO4 (385.3192)


   

hexacosapentaenoate

hexacosapentaenoate

C26H41O2 (385.3106)


A polyunsaturated fatty acid anion that is the conjugate base of hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-(hydroxytetradecenoyl)carnitine

O-(hydroxytetradecenoyl)carnitine

C21H39NO5 (385.2828)


An O-acylcarnitine in which the acyl group specified is hydroxytetradecenoyl.

   

O-pentadecanoylcarnitine

O-pentadecanoylcarnitine

C22H43NO4 (385.3192)


An O-acylcarnitine in which the acyl group is specified as pentadecanoyl.

   

CarE(14:1)

CarE(14:1(1+O))

C21H39NO5 (385.2828)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

AcCa(15:0)

AcCa(15:0)

C22H43NO4 (385.3192)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   

n-[1-(acetyloxy)-3-hydroxyoctadecan-2-yl]ethanimidic acid

n-[1-(acetyloxy)-3-hydroxyoctadecan-2-yl]ethanimidic acid

C22H43NO4 (385.3192)


   

3-hydroxy-2-octadecylindole

NA

C26H43NO (385.3344)


{"Ingredient_id": "HBIN008643","Ingredient_name": "3-hydroxy-2-octadecylindole","Alias": "NA","Ingredient_formula": "C26H43NO","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8096","PubChem_id": "NA","DrugBank_id": "NA"}

   

7alpha-Hydroxyconessine

7α-hydroxyconessine; 7alpha-hydroxyconessine

C26H43NO (385.3344)


{"Ingredient_id": "HBIN013039","Ingredient_name": "7alpha-Hydroxyconessine","Alias": "7\u03b1-hydroxyconessine; 7alpha-hydroxyconessine","Ingredient_formula": "C26H43NO","Ingredient_Smile": "CC1CC2C3C(CCC24C1C(N(C4)C)C)C5(CCC(CC5=CC3O)C(C)C)C","Ingredient_weight": "385.7","OB_score": "12.75733618","CAS_id": "NA","SymMap_id": "SMIT01145","TCMID_id": "31171;9931","TCMSP_id": "MOL003439","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

n-[(2s,3r)-1-(acetyloxy)-3-hydroxyoctadecan-2-yl]ethanimidic acid

n-[(2s,3r)-1-(acetyloxy)-3-hydroxyoctadecan-2-yl]ethanimidic acid

C22H43NO4 (385.3192)


   

5-(henicosa-12,15-dien-1-yl)-1h-pyrrole-2-carbaldehyde

5-(henicosa-12,15-dien-1-yl)-1h-pyrrole-2-carbaldehyde

C26H43NO (385.3344)


   

1-[(1s,3r,6s,8r,11s,12s,14r,15r,16r)-6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone

1-[(1s,3r,6s,8r,11s,12s,14r,15r,16r)-6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone

C25H39NO2 (385.2981)


   

(3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

(3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

C25H39NO2 (385.2981)


   

5-[(12z,15z)-henicosa-12,15-dien-1-yl]-1h-pyrrole-2-carbaldehyde

5-[(12z,15z)-henicosa-12,15-dien-1-yl]-1h-pyrrole-2-carbaldehyde

C26H43NO (385.3344)


   

(12z)-n-benzyl-9-oxooctadec-12-enimidic acid

(12z)-n-benzyl-9-oxooctadec-12-enimidic acid

C25H39NO2 (385.2981)


   

(1s,3s,8r,11s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

(1s,3s,8r,11s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

C25H39NO2 (385.2981)


   

n-benzyl-9-oxooctadec-12-enimidic acid

n-benzyl-9-oxooctadec-12-enimidic acid

C25H39NO2 (385.2981)


   

(1s,3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

(1s,3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one

C25H39NO2 (385.2981)


   

1-[6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone

1-[6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone

C25H39NO2 (385.2981)